Cardinal Health Q3 non-GAAP EPS $2.35, up 13% YoY; raises FY25 EPS guidance to $8.05-$8.15

CARDINAL HEALTH INC

Revenue $54.9B flat YoY; up 19% ex-customer contract expiration.
GAAP diluted EPS $2.10; non-GAAP $2.35, up 13% on 21% non-GAAP op earnings growth.
Pharma & Specialty segment profit $662M (+14%); Medical segment profit $39M (+77%).
FY25 non-GAAP EPS guidance raised to $8.05-$8.15 from $7.85-$8.00.
Completed acquisition of Advanced Diabetes Supply Group on Apr 1; $375M ASR program executed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.